Exploring the Next Generation of Metabolic Science
Retatrutide is an investigational, once-weekly triple hormone receptor agonist that activates the receptors for GIP, GLP-1, and glucagon. This unique mechanism has made retatrutide an important area of research in metabolic and cardiometabolic science.
Clinical research is evaluating retatrutide in areas including body-weight regulation, glucose metabolism, cardiovascular health, sleep apnea, and other obesity-related conditions. Phase 3 trials have reported substantial changes in body weight and glycemic measures, while ongoing research continues to evaluate its overall safety and efficacy.
Research Focus
GIP, GLP-1 & glucagon receptor signaling
Appetite and energy-balance pathways
Glucose and metabolic regulation
Body-weight research
Cardiometabolic health
Next-generation incretin biology
Research Status: Investigational Not currently FDA-approved
